THE ROLE OF GALECTIN-1 IN HAEMATOLOGIC MALIGNANCIES TREATED WITH NON-MYELOABLATIVE HAEMOPOIETIC STEM CELL TRANSPLANTATION

IRMA PETRUSKEVICIUS,; MAJA LUDVIGSEN,; RIKKE HJORTEBJERG,; BETINA S. SØRENSEN,; BENDT NIELSEN,; BENT HONORÉ,; PETER KAMPER, ; MAJA VASE; APARNA UDUPI, ; PETER HOKLAND1,; GABRIEL A. RABINOVICH ; FRANCESCO A. D?AMORE

BONE MARROW TRANSPLANTATION

NATURE PUBLISHING GROUP

Lugar: Londres; Año: 2016

0268-3369

Galectin-1 (Gal-1), a glycan-binding protein present in inflammatory and tumor microenvironments, has demonstrated important roles in immune cell activation, differentiation and homeostasis. We investigated the impact of Gal-1 serum levels measured before non-myeloablative haemopoietic stem cell transplantation (NM-HSCT) in the clinical outcome of 57 patients with haematologic malignancies. The median time to engraftment was 19 days (range 8-27) in patients with low Gal-1 levels vs. 21 days (range 11-24) in patients with high Gal-1 levels, p=0.299. The incidence of aGvHD in patients with low vs. high Gal-1 levels was 36 % and 48 %, respectively, p=0.574. After 15 months the incidence of cGvHD in patients with low vs. high Gal-1 levels was 80% and 39%, respectively, p=0.052. PFS at 100 days. However, 12 and 24 months after transplantation the incidence reached levels of 96 %, 92 % and 92 % in patients with low Gal-1 vs. 93 %, 85 % and 80 % in patients with high Gal-1 levels, p=0.319. In addition, OS at 100 days, 12 and 24 months after transplantation was 96 % , 73 % and 73 % in patients with low Gal-1 levels vs. 100 %, 88 % and 79 % in patients with high Gal-1 levels, p=0.259. The cumulative incidence of TRM at 100 days, 12 and 24 months after transplantation was 3.7 %, 25 % and 25 % in patients with low Gal-1 levels, while no TRM events were recorded among patients with high Gal-1 levels. Our results suggest that low Gal-1 levels before NM-HSCT predict a higher incidence of cGvHD and TRM in patients with haematologic malignancies.